Nektar Therapeutics

NKTRPhase 3

Nektar Therapeutics is focused on developing transformative medicines that resolve immune imbalances to treat autoimmune and inflammatory conditions. The company's pipeline is anchored by rezpegaldesleukin, a Treg-targeting biologic in advanced Phase 2b studies, and NKTR-0165, a preclinical TNFR2 agonist. With a seasoned leadership team and a history of successful partnerships leading to approved medicines, Nektar is advancing a portfolio of first-in-class candidates with significant disease-modifying potential.

Market Cap

$2.1B

Focus

BiologicsSmall Molecules

NKTR · Stock Price

USD 72.2212.08 (-14.33%)

Historical price data

AI Company Overview

Technology Platform

Platform focused on immuno-modulation, developing agonists that selectively target and expand regulatory T cells (Tregs) to restore immune homeostasis, acting upstream of multiple pro-inflammatory pathways.

Pipeline Snapshot

34 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
NKTR-181 BID tablets + Placebo to match NKTR-181 BID tablets	Low Back Pain	Phase 3
NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Doc...	Metastasis	Phase 3
NKTR-181 BID tablets	Low Back Pain	Phase 3
NKTR-102 + Treatment of Physician's Choice (TPC)	Locally Recurrent Breast Cancer	Phase 3
NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kg	Non-Hodgkin Lymphoma	Phase 2/3

Funding History

Total raised: $350M

Debt$150MHealthcare Royalty PartnersJun 15, 2020

PIPE$200MBaker Bros. AdvisorsMar 15, 2018

IPOUndisclosedUndisclosedJun 15, 1994

Opportunities

Positive Phase 2b data for rezpegaldesleukin could validate its novel Treg mechanism and unlock significant value in large autoimmune markets like atopic dermatitis and alopecia areata.

Expansion into Type 1 diabetes offers a high-impact opportunity for disease modification.

The preclinical TNFR2 agonist program represents a promising new avenue in immuno-modulation.

Risk Factors

High clinical development risk concentrated on a single lead asset (rezpegaldesleukin).

Intense competition from established and emerging therapies in all target indications.

Financial risk associated with funding late-stage development as a pre-revenue company.

Competitive Landscape

Faces competition from blockbuster biologics (e.g., Dupixent) and JAK inhibitors in dermatology. Key differentiation is rezpegaldesleukin's upstream, immunomodulatory mechanism targeting Treg expansion, which aims for broad efficacy and potential disease modification versus targeted pathway inhibition.

Publications

Patents

Pipeline